Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Regen Biopharma, Inc. (OTC: RGBPP).

Full DD Report for RGBPP

You must become a subscriber to view this report.


Recent News from (OTC: RGBPP)

Regen BioPharma, Inc. Files New Composition of Matter Patent Application Based on Its Successful Modulation of NR2F6 by Its Small Molecule Compounds
SAN DIEGO , September 6, 2018 /PRNewswire/ -- Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has filed a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate NR2F6 ("Small Molecule Agonis...
Source: PR Newswire
Date: September, 06 2018 16:00
Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases
SAN DIEGO , August 30, 2018 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently identified novel chemical compounds appear to inhibit NR2F6 and...
Source: PR Newswire
Date: August, 30 2018 09:00
No Toxicity Seen in Mice as Regen BioPharma, Inc. Finishes Initial Optimization of its Lead NR2F6 Small Molecule Agonist
SAN DIEGO , July 23, 2018 /PRNewswire/ -- Regen BioPharma Inc.'s (OTCQB: RGBP) and (OTCQB: RGBPP) lead candidate drug, RG-NAE005, was tested for its maximum tolerated dose in mice and showed no signs of toxicity. Regen has methodically optimized small molecules that bind to, and activat...
Source: PR Newswire
Date: July, 23 2018 00:48
Regen BioPharma, Inc. Nears Completion of Optimizing its Lead NR2F6 Small Molecule Agonist
SAN DIEGO , March 21, 2018 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the primary and back up compounds being read...
Source: PR Newswire
Date: March, 21 2018 08:00
Regen BioPharma, Inc. Program to Determine the 3-D Crystal Structure of NR2F6 Progresses to Next Step
SAN DIEGO , February 21, 2018 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has moved into the second stage of its previously-announced program to determine the three-dimensional structure of NR2F6 - with and without its proprietary small molecule drugs bound to ...
Source: PR Newswire
Date: February, 21 2018 08:00
Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6
SAN DIEGO , January 17, 2018 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. Th...
Source: PR Newswire
Date: January, 17 2018 08:00
Regen BioPharma, Inc. Files Additional Composition of Matter Patent Application on NR2F6-Modulating Small Molecules
SAN DIEGO , December 11, 2017 /PRNewswire/ -- Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today announced filing a patent application covering composition of matter and methods of use related to molecules identified in its small molecule program that activate and inhibit NR2F...
Source: PR Newswire
Date: December, 11 2017 08:00
Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor
SAN DIEGO, California , November 27, 2017 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has initiated in vivo and ex vivo assessments to determine the effects of some of the Company's NR2F6 small molecule agonists in live rats and in tissues derived from huma...
Source: PR Newswire
Date: November, 27 2017 18:26
Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6
SAN DIEGO , November 16, 2017 /PRNewswire/ -- 18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune ce...
Source: PR Newswire
Date: November, 16 2017 16:01
Regen BioPharma's Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs
SAN DIEGO , November 8, 2017 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor. In addition, the Company recently reported that its NR2F6 medicinal chemistry program i...
Source: PR Newswire
Date: November, 08 2017 18:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0060.00520.00750.0052124,069
2018-12-130.00770.00830.00830.00652,203
2018-12-12N/A0.00649N/AN/A1
2018-12-110.006490.006490.006490.00649370
2018-12-100.0090.0120.0120.009102,422

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1425,299124,06920.3911Cover
2018-12-1330,50052,20358.4258Short
2018-12-1019,827102,42219.3581Cover
2018-12-07194,750281,37069.2149Short
2018-11-2866,25586,30376.7702Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RGBPP.


About Regen Biopharma, Inc. (OTC: RGBPP)

Logo for Regen Biopharma, Inc. (OTC: RGBPP)

Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre clinical and Phase I/II clinical trials. Currently the Company is developing products treating blood disorders using small molecules and gene silencing DiffronC , treating cancer with immunotherapy dCellVax , modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches BORIS , and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients HemaXellerate .

 

 

 

Current Management

  • David Koos / CEO
    • David Koos is the Founder, Chairman amp CEO of Regen BioPharma Inc. Dr. Koos has over years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or coauthored numerous peer reviewed journal articles primarily on biotechnology related subjects.
  • Todd Caven / CFO
    • Todd S. Caven is an accomplished executive with years of experience in corporate finance, taxation, mergers amp acquisitions, corporate valuations and financing activities for various types of transactions. In March of , Mr. Caven cofounded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States. Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
  • Dr. Harry M. Lander / CSO, President
    • Dr.Lander received an MBA in Finance from The New York University Stern School of Business in New York City in and a Ph.D. in Biochemistry from the Cornell University Graduate School of Medical Sciences. Dr. Lander has also earned a Bachelor of Science in Biochemistry and a Bachelor of Science in Chemistry from State University of New York at Stony Brook. Prior to accepting the office of President at Regen, Dr. Lander served as Research ChiefAdministration at Sidra Medical and Research Center, a new women and children s hospital expected to open in established to provide care to Qatari and Middle East residents based on the North American academic medical center model. His duties at the Medical and Research Center included assisting in the development of financial, operational , and compliance infrastructures for the Center as well as assisting in developing the Center s scientific strategy through a year strategic plan
  • David Koos / Chairman
    • David Koos is the Founder, Chairman amp CEO of Regen BioPharma Inc. Dr. Koos has over years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or coauthored numerous peer reviewed journal articles primarily on biotechnology related subjects.

Current Share Structure

  • Market Cap: $6,422,441 - 03/09/2018
  • Authorized: 300,000,000 - 01/04/2017
  • Issue and Outstanding: 139,466,697 - 02/21/2017
  • Float: 98,748,817 - 01/04/2017

 


Recent Filings from (OTC: RGBPP)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 06 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: January, 05 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: December, 28 2017

 

 


Daily Technical Chart for (OTC: RGBPP)

Daily Technical Chart for (OTC: RGBPP)


Stay tuned for daily updates and more on (OTC: RGBPP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RGBPP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RGBPP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RGBPP and does not buy, sell, or trade any shares of RGBPP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/